Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 5:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: D5W Placebo Clear all
Completed Phase 3 Interventional

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

NCT04799249
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer, Breast Cancer
Interventions
Trilaciclib, Placebo, Gemcitabine, Carboplatin
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Gilbert, Arizona • Washington D.C., District of Columbia • St. Petersburg, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available

Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis

NCT03829683
View directory record Official record
Conditions
Alcoholic Hepatitis, Sepsis
Interventions
Vitamin C, Dextrose 5% in water
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 4 Interventional Results available

Study of High Dose Vitamin C On Outcome in Cardiac Surgery Patients

NCT01167569
View directory record Official record
Conditions
Reperfusion Injury
Interventions
Ascorbic Acid, 5 % Dextrose Water or Normal Saline
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients

NCT02802228
View directory record Official record
Conditions
Portal Hypertension, Liver Cirrhosis
Interventions
Ifetroban, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Tampa, Florida • Indianapolis, Indiana • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

NCT02592798
View directory record Official record
Conditions
Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions
Abatacept, Normal Saline, D5W
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
27
States / cities
Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 2 Interventional

Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke

NCT04918719
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Acetylcysteine, Dextrose in Water
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 4 Interventional Results available

MRI and Neurodevelopment in Preterm Infants Following Administration of High-Dose Caffeine

NCT00809055
View directory record Official record
Conditions
Apnea of Prematurity, Intraventricular Hemorrhage, Brain Injury
Interventions
Caffeine citrate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
24 Weeks to 30 Weeks
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Sep 6, 2026, 5:24 AM EDT
Terminated Phase 2 Interventional Results available

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)

NCT04863248
View directory record Official record
Conditions
Metastatic Non-Small Cell Lung Cancer, NSCLC, Lung Cancer
Interventions
Trilaciclib, Placebo, Docetaxel
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Rancho Mirage, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of IV Infusion of TZP-101 for POI After Major Open Abdominal Surgery

NCT00617552
View directory record Official record
Conditions
Postoperative Ileus
Interventions
5% dextrose in water, TZP-101
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
10
States / cities
Los Angeles, California • Miami, Florida • Ocala, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Tariquidar-ondansetron Combination in Neuropathic Pain

NCT04603066
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Ondansetron 16 mg with Tariquidar, Ondansetron 16 mg with Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Sep 6, 2026, 5:24 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Ceftriaxone for Post-Treatment Lyme Disease

NCT06785402
View directory record Official record
Conditions
Post-Treatment Lyme Disease Syndrome
Interventions
Ceftriaxone treatment, Placebo
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

NCT01746979
View directory record Official record
Conditions
Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Interventions
TH-302, Gemcitabine, Placebo (5 percent dextrose - D5W)
Drug
Lead sponsor
ImmunoGenesis
Industry
Eligibility
18 Years and older
Enrollment
693 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis

NCT00612014
View directory record Official record
Conditions
Gastroparesis, Diabetes Mellitus
Interventions
5% dextrose in water, TZP-101
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
San Francisco, California • Anderson, Indiana • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis

NCT00048932
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Double-blind Abatacept, Double-blind Placebo, Open-label Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
44
States / cities
Decatur, Alabama • Paradise, Arizona • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Sep 6, 2026, 5:24 AM EDT
Recruiting Early Phase 1 Interventional

Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease

NCT06611111
View directory record Official record
Conditions
Post-Treatment Lyme Disease
Interventions
Ceftriaxone (Rocephin®), Dextrose 5% (D5W)
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
East Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 4 Interventional Results available

Effect of Valproic Acid Concentration on Photic Response

NCT00609245
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
15 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chesterfield, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 3 Interventional Results available

Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01811732
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections
Interventions
Delafloxacin, Vancomycin, Aztreonam, Placebo
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
Montgomery, Alabama • Anaheim, California • Chula Vista, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ANX-042 Healthy Volunteer Dose Escalation Study

NCT01638104
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ANX-042, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
19 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome

NCT03019653
View directory record Official record
Conditions
Heart Failure, Cardiorenal Disease, Renal Disfunction
Interventions
ANX-042, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 6, 2026, 5:24 AM EDT
Recruiting Phase 3 Interventional

NAC vs Placebo on Opioid Use for Hysterectomy

NCT06039566
View directory record Official record
Conditions
Hysterectomy
Interventions
IV N-acetylcysteine, IV Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers

NCT02471690
View directory record Official record
Conditions
Healthy
Interventions
Oritavancin, Dextrose
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 6, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available

Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients

NCT01436500
View directory record Official record
Conditions
Hepatorenal Syndrome
Interventions
Ifetroban Injection, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 6, 2026, 5:24 AM EDT
Terminated Phase 2 Interventional Results available

Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery

NCT00543309
View directory record Official record
Conditions
Heart Defects, Congenital
Interventions
nesiritide, milrinone, placebo
Drug
Lead sponsor
John M Costello
Other
Eligibility
Not listed
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2018 · Synced Sep 6, 2026, 5:24 AM EDT
Terminated Phase 2 Interventional Results available

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

NCT04323436
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Spartalizumab, Capmatinib, spartalizumab placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 6, 2026, 5:24 AM EDT